1. Home
  2. KBDC vs DRTS Comparison

KBDC vs DRTS Comparison

Compare KBDC & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kayne Anderson BDC Inc.

KBDC

Kayne Anderson BDC Inc.

HOLD

Current Price

$13.99

Market Cap

980.7M

Sector

N/A

ML Signal

HOLD

Logo Alpha Tau Medical Ltd.

DRTS

Alpha Tau Medical Ltd.

HOLD

Current Price

$9.40

Market Cap

978.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KBDC
DRTS
Founded
2021
2015
Country
United States
Israel
Employees
N/A
121
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
980.7M
978.2M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
KBDC
DRTS
Price
$13.99
$9.40
Analyst Decision
Buy
Strong Buy
Analyst Count
5
3
Target Price
$15.50
$8.67
AVG Volume (30 Days)
226.4K
1.0M
Earning Date
05-11-2026
05-18-2026
Dividend Yield
13.16%
N/A
EPS Growth
N/A
N/A
EPS
0.43
N/A
Revenue
N/A
N/A
Revenue This Year
$193.84
N/A
Revenue Next Year
$9.00
$699.98
P/E Ratio
$32.63
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.06
$2.87
52 Week High
$16.28
$11.62

Technical Indicators

Market Signals
Indicator
KBDC
DRTS
Relative Strength Index (RSI) 38.37 48.85
Support Level $13.52 $6.59
Resistance Level $14.30 $11.48
Average True Range (ATR) 0.33 0.90
MACD -0.07 -0.13
Stochastic Oscillator 5.59 25.19

Price Performance

Historical Comparison
KBDC
DRTS

About KBDC Kayne Anderson BDC Inc.

Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company, investing mainly in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation mainly through debt investments in middle-market companies.

About DRTS Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.

Share on Social Networks: